| Michael B Rath, MD | |
|
1809 Adams St, Mankato Clinic @ Adams Street, Mankato, MN 56001-4841 | |
| (507) 625-1811 | |
| Not Available |
| Full Name | Michael B Rath |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 1809 Adams St, Mankato, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013996008 | NPI | - | NPPES |
| 0101172 | Other | MN | MEDICA |
| 238287300 | Medicaid | MN | |
| HP25865 | Other | MN | HEALTH PARTNERS |
| 1694592 | Other | MN | AMERICAS PPO |
| 938357 | Medicaid | IA | |
| NA2951023857 | Other | MN | PREFERRED ONE |
| 120210 | Other | MN | UCARE |
| 41084933956001C036 | Other | CHAMPUS | |
| 080068439 | Other | RR MEDICARE | |
| 18149RA | Other | MN | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 22937 (Minnesota) | Primary |
| Entity Name | St Francis Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891954574 PECOS PAC ID: 8123937992 Enrollment ID: O20040429000995 |
News Archive
One in three people is plagued by an allergy, triggered by foodstuffs, fungi, house dust mites or on a seasonal basis due to pollen. The latter group is the largest: around 800 million people worldwide suffer from some form of allergy to pollen, with the usual symptoms such as a runny nose, cough and severe breathing problems.
The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.
The study, published in the September issue of the Annals of Otology, Rhinology and Laryngology, found that patients who received platelet gel reported an easier recovery than patients who received traditional packing to stop bleeding.
Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort AQ (triamcinolone acetonide) nasal spray, Allegra D-12 Hour (fexofenadine hydrochloride 60mg and pseudoephedrine hydrochloride 120mg) extended-release tablets, and Allegra (fexofenadine) 30mg, 60mg and 180mg tablets.
Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its operating subsidiary Slavica Bio Chem, announces that it is targeting an EU based company, and has initiated talks that may involve a merger.
› Verified 3 days ago
| Entity Name | Sanford Health Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699869875 PECOS PAC ID: 6800707100 Enrollment ID: O20040715001116 |
News Archive
One in three people is plagued by an allergy, triggered by foodstuffs, fungi, house dust mites or on a seasonal basis due to pollen. The latter group is the largest: around 800 million people worldwide suffer from some form of allergy to pollen, with the usual symptoms such as a runny nose, cough and severe breathing problems.
The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.
The study, published in the September issue of the Annals of Otology, Rhinology and Laryngology, found that patients who received platelet gel reported an easier recovery than patients who received traditional packing to stop bleeding.
Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort AQ (triamcinolone acetonide) nasal spray, Allegra D-12 Hour (fexofenadine hydrochloride 60mg and pseudoephedrine hydrochloride 120mg) extended-release tablets, and Allegra (fexofenadine) 30mg, 60mg and 180mg tablets.
Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its operating subsidiary Slavica Bio Chem, announces that it is targeting an EU based company, and has initiated talks that may involve a merger.
› Verified 3 days ago
| Entity Name | St Francis Medical Center |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1639162381 PECOS PAC ID: 8123937992 Enrollment ID: O20080303000129 |
News Archive
One in three people is plagued by an allergy, triggered by foodstuffs, fungi, house dust mites or on a seasonal basis due to pollen. The latter group is the largest: around 800 million people worldwide suffer from some form of allergy to pollen, with the usual symptoms such as a runny nose, cough and severe breathing problems.
The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.
The study, published in the September issue of the Annals of Otology, Rhinology and Laryngology, found that patients who received platelet gel reported an easier recovery than patients who received traditional packing to stop bleeding.
Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort AQ (triamcinolone acetonide) nasal spray, Allegra D-12 Hour (fexofenadine hydrochloride 60mg and pseudoephedrine hydrochloride 120mg) extended-release tablets, and Allegra (fexofenadine) 30mg, 60mg and 180mg tablets.
Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its operating subsidiary Slavica Bio Chem, announces that it is targeting an EU based company, and has initiated talks that may involve a merger.
› Verified 3 days ago
| Entity Name | Rural Health Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215317375 PECOS PAC ID: 3476447541 Enrollment ID: O20150710000034 |
News Archive
One in three people is plagued by an allergy, triggered by foodstuffs, fungi, house dust mites or on a seasonal basis due to pollen. The latter group is the largest: around 800 million people worldwide suffer from some form of allergy to pollen, with the usual symptoms such as a runny nose, cough and severe breathing problems.
The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.
The study, published in the September issue of the Annals of Otology, Rhinology and Laryngology, found that patients who received platelet gel reported an easier recovery than patients who received traditional packing to stop bleeding.
Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort AQ (triamcinolone acetonide) nasal spray, Allegra D-12 Hour (fexofenadine hydrochloride 60mg and pseudoephedrine hydrochloride 120mg) extended-release tablets, and Allegra (fexofenadine) 30mg, 60mg and 180mg tablets.
Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its operating subsidiary Slavica Bio Chem, announces that it is targeting an EU based company, and has initiated talks that may involve a merger.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael B Rath, MD 1230 E Main St, Po Box 8674 Mankato Clinic Ltd, Mankato, MN 56002-8674 Ph: (507) 625-1811 | Michael B Rath, MD 1809 Adams St, Mankato Clinic @ Adams Street, Mankato, MN 56001-4841 Ph: (507) 625-1811 |
News Archive
One in three people is plagued by an allergy, triggered by foodstuffs, fungi, house dust mites or on a seasonal basis due to pollen. The latter group is the largest: around 800 million people worldwide suffer from some form of allergy to pollen, with the usual symptoms such as a runny nose, cough and severe breathing problems.
The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.
The study, published in the September issue of the Annals of Otology, Rhinology and Laryngology, found that patients who received platelet gel reported an easier recovery than patients who received traditional packing to stop bleeding.
Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort AQ (triamcinolone acetonide) nasal spray, Allegra D-12 Hour (fexofenadine hydrochloride 60mg and pseudoephedrine hydrochloride 120mg) extended-release tablets, and Allegra (fexofenadine) 30mg, 60mg and 180mg tablets.
Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its operating subsidiary Slavica Bio Chem, announces that it is targeting an EU based company, and has initiated talks that may involve a merger.
› Verified 3 days ago
Sangil Lee, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1025 Marsh St, Mankato, MN 56001 Phone: 507-254-6121 | |
Alyssa L Stitt, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1230 E Main Street, Mankato Clinic, Mankato, MN 56002 Phone: 507-625-1811 | |
Richard J Peller, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1421 Premier Dr, Mankato Clinic, Mankato, MN 56001 Phone: 507-625-1811 | |
Corina Narvaez Jacob, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 Martin Luther King Dr, Mankato, MN 56001 Phone: 507-385-6500 | |
Abdifatah Abdullahi Ahmed, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 101 Martin Luther King Jr. Dr, Mankato, MN 56001 Phone: 507-594-6572 | |
Artika Misra, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1025 Marsh St, Mankato, MN 56001 Phone: 507-625-4031 |